About 200 reports

  • 6.1.5.2 IMATINIB(GLEEVEC)
  • Acute Myeloid Leukemia Therapeutics Market: Revenue in USD million, Tyrosine Kinase Inhibitors, Imatinib, Global, 2015-2023

TABLE OF CONTENTS ##.

  • Leukemia
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Genmab group
  • Novartis AG
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY ARIAD PHARMACEUTICALS INC, H1 2018
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY AROG PHARMACEUTICALS INC, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology)...

  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR

It is also in development within the gastrointestinal disease area.

  • Leukemia
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

  • Leukemia
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Supply
  • Tianjin Tianyao Pharmaceutical Co., Ltd
  • Zhejiang Expressway Co., Ltd.

One reason for noncompliance is safety issues.

  • Leukemia
  • United States
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG

THE MOST COMMON GRADE ## OR ## ADVERSE EVENTS INCLUDE GASTROINTESTINAL EVENTS SUCH AS NAUSEA, VOMITING, AND DIARRHEA (VIDAZA PRESCRIBING INFORMATION, 2014).

  • Leukemia
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Nanjing Aosaikang Medicinal Group
  • Zhejiang Expressway Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

FOR INSTANCE, ONE PATIENT HAD GASTROINTESTINAL HEMORRHAGE (POST ## DAYS OF ADMINISTRATION OF SINGLE ##. ## MG DOSE).

  • Leukemia
  • North America
  • United States
  • Ablynx NV
  • Amgen Inc.

Grade ## fatigue (n = ##) and AST increase (n = ##) were also observed at the ##mg dose.

  • Leukemia
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis AG
  • PRESS RELEASE 4

Most common adverse events were grade ##-## and gastrointestinal in nature.

  • Leukemia
  • United States
  • Demand
  • Celgene Corporation
  • Nippon Shinyaku Co., Ltd.

OTHER PRODUCTS ARE IN DEVELOPMENT IN RESPIRATORY CONDITIONS, BACTERIAL INFECTIONS, CNS/ PAIN, AND GASTROINTESTINAL DYSFUNCTION.

  • Leukemia
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 1ZIABC0 06198-26
  • 1ZIABC0 11564-01

IN ADDITION, THE STUDY SHOWED THIS ADC HAS MANAGEABLE NEUTROPENIA AND GASTROINTESTINAL TOXICITIES.

  • Leukemia
  • North America
  • United States
  • Market Size
  • Seattle Genetics, Inc.
  • GLEEVEC DRUG PROFILE

Lancet Oncology, ##(##), ##-##.

  • Leukemia
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • MERCK & CO., INC.

FINDINGS: May ##, 2015 ## Among these subgroup of subjects, more common grade ## or higher non-hematologic adverse events in the vosaroxin combination arm include gastrointestinal and myelosuppression-related toxicities, consistent with those observed in previous company studies.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • Therapy
  • World

THE MOST FREQUENT ADVERSE EVENTS REPORTED WERE ASTHENIA AND GASTROINTESTINAL DISORDERS. ## PERCENT (EIGHT OUT OF ## PATIENTS) SHOWED AN OBJECTIVE RESPONSE INCLUDING THREE WHO SHOWED COMPLETE REMISSION.

  • Leukemia
  • North America
  • United States
  • Amgen Inc.
  • MedImmune, LLC

The most common Grade ## or ## adverse events include gastrointestinal events such as nausea, vomiting, and diarrhea (Vidaza prescribing information, 2014).

  • Leukemia
  • Astellas Pharma Inc.
  • Celator Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG

Nature Education, ##(##), ##.

  • Leukemia
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Target
  • Clinical Trial profile. 41 Trial Title

## ## ## ## ## ## ## ## ## ## ## ## GlaxoSmithKline Plc Galera Therapeutics Inc Novartis AG ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## MallInckrodt Plc Jazz Pharmaceuticals Plc Eisai Co Ltd CD Pharma India Pvt Ltd Biotec Pharmacon ASA Sourc

  • Cancer
  • Clinical Trial
  • Leukemia
  • World
  • Product Initiative
  • Sareum Holdings Plc - Pipeline by Indication, 2016

SART-## acts as a tyrosine kinase ## (TYK##) inhibitor.

  • Leukemia
  • China
  • World
  • Company Operations
  • Sareum Holdings plc
  • Tasigna: Orphan Drug Designation

Appendix ##: List of Companies and Organizations ##.

  • Leukemia
  • North America
  • United States
  • Novartis AG
  • Pfizer Inc.
  • Products under Development by Companies, H2 2017
  • Global Markets Direct Report Coverage

Gastrointestinal events were predominantly grade ##/ ##, early in onset, and usually subsided within a month. ## DAS-I pts had grade ## pleural effusions; both had these events on prior DAS and were grade ## on study entry.

  • Cancer
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Leukemia
  • United States
  • World
  • Product Initiative
  • Sareum Holdings plc
  • Clinical Trial profile. 18 Trial Title
  • Clinical Trial profile. 32 Trial Title

Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Cou

  • Dermatological Condition
  • Leukemia
  • Therapy
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

One patient had a Sprycel-related AE leading to discontinuation, and one patient died from gastrointestinal bleeding unrelated to treatment.

  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA

High Mobility Group Protein B## (High Mobility Group Protein ## or High Mobility Group Protein Box ## or HMGB##) - Overview High mobility group box ## protein also known as high-mobility group protein ## (HMG-##) is a protein encoded by the HMGB## gene.

  • Leukemia
  • United States
  • World
  • Product Initiative
  • Cantex Pharmaceuticals, Inc.
  • selected advanced gastrointestinal and genitourinary tumors. The trial was registered with the U.S. National Institutes of Health.
  • REFRACTORY ACUTE MYELOID LEUKEMIA - PIPELINE BY AROG PHARMACEUTICALS, INC., H1 2016

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2016’, provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under...

  • Leukemia
  • Therapy
  • United States
  • Company
  • Product Initiative
  • the U.S. National Institutes of Health.
  • VOLASERTIB TRIHYDROCHLORIDE - DRUG PROFILE

The drug targets polo-like kinase ## (PLK-##).

  • Leukemia
  • United States
  • World
  • Product Initiative
  • Onconova Therapeutics, Inc.

Common toxicities were hematological and gastrointestinal.

  • Breast Cancer
  • Leukemia
  • United States
  • Product Initiative
  • Syndax Pharmaceuticals, Inc.
  • pexidartinib - Drug Profile

As of October 2014, it was in Phase II stage for gastrointestinal stromal tumors (second/ third line).

  • Leukemia
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Plexxikon Inc.